XML 28 R17.htm IDEA: XBRL DOCUMENT

Subsequent Events	9 Months Ended
Subsequent Events	Jun. 30, 2018
Subsequent Events [Abstract]
Subsequent Events	NOTE 10. SUBSEQUENT EVENTS On August 1, 2018, the Company announced that it had earned a $10 million milestone payment from Amgen following the administration of the first dose of AMG 890 (ARO-LPA) in a phase 1 clinical study. The Company will recognize this payment as revenue in its entirety during the fourth fiscal quarter of 2018.